Depuis 2013, le Programme de recherche en don et transplantation du Canada (PRDTC) soutient la recherche et l’innovation qui s’attaque aux obstacles dans les domaines du don et de la transplantation, dans le but ultime de faire progresser les résultats de santé à long terme ainsi que la qualité de vie des patients canadiens ayant subi une transplantation.
Grâce à des partenariats stratégiques avec plusieurs partenaires clés dans tout le Canada, le PRDTC a maintenu son engagement en faveur de la recherche et du développement au sein de la communauté scientifique de transplantation par le lancement continu des Concours de subventions pour l’innovation en recherche du PRDTC. Cet effort de collaboration entre le PRDTC et nos partenaires vise à lancer de nouveaux projets pilotes innovants dans le domaine du don et de la transplantation.
Depuis 2013, le Programme de recherche en don et transplantation du Canada (PRDTC) soutient la recherche et l’innovation qui s’attaque aux obstacles dans les domaines du don et de la transplantation, dans le but ultime de faire progresser les résultats de santé à long terme ainsi que la qualité de vie des patients canadiens ayant subi une transplantation.
Grâce à des partenariats stratégiques avec plusieurs partenaires clés dans tout le Canada, le PRDTC a maintenu son engagement en faveur de la recherche et du développement au sein de la communauté scientifique de transplantation par le lancement continu des Concours de subventions pour l’innovation en recherche du PRDTC. Cet effort de collaboration entre le PRDTC et nos partenaires vise à lancer de nouveaux projets pilotes innovants dans le domaine du don et de la transplantation.
Pour le concours de 2024, le PRDTC est fier de s’associer aux organisations suivantes pour financer un total de 9 subventions de 30 000 $ canadiens chacune :
- Takeda Canada [1]
- Transplant Research Foundation of British Columbia:
- The Venture Grants [2]
- La Fondation canadienne du rein [2]
- Alberta Transplant Institute / Paladin Labs Inc. [1]
- London Health Sciences Centre [1]
- Université de Montréal [2]
Les sections ci-bas sont disponibles en anglais uniquement
The Principal Applicant must:
- Be an independent researcher working at a Canadian University or research institution.
- Be a Canadian resident and conduct the research at a Canadian institution (study subjects may be enrolled from other countries).
- Agree to integrate their study within the CDTRP structure if funded and agree to become a participating CDTRP Investigator.
- Patient, family and donors (PFD) partners involved in the project are expected to join the CDTRP Patient, Family, and Donor Partnership Platform.
- All stages of research career are eligible for funding, but CDTRP wants to give priority to Early Career Researchers (in the first five years of their academic appointment).
- Postdoctoral research trainees are invited to apply with their supervisor or director as co-principal applicants.
- Agree to sign a Research Grant Acceptance Form with the CDTRP.
- Agree to provide progress reports, including publication plan, to the CDTRP in dissemination of study results.
- Agree to publish their work on behalf of the CDTRP and list the CDTRP as an author affiliation.
- Agree to acknowledge the CDTRP and relevant partner funding on any related publications arising from the study.
- If successful, agree to have their application shared in confidence with the relevant funding partner for internal documentation and auditing purposes.
- Agree that any partner funder may disclose the amount and nature of the grant publicly on its website and in connection with any other public disclosure of payments/funding to healthcare professionals and healthcare organizations.
- Investigators who receive CDTRP ATI/Paladin Research Innovation Grants are expected to become members of the ATI if they are not members at the time of application.
Eligible Research Proposals
In 2024, the research proposals being considered will be those that address CDTRP’s mission, which is to drive advances in Canadian donation and transplantation research and mobilize knowledge so that every wish to donate is fulfilled and transplantation is transformed from a treatment to a lasting and sustainable cure.
This funding is intended to support new/pilot projects that have not been previously funded and where this funding could help the researcher become competitive for large/national level grant funding. The research proposal must align with one of the 5 Themes of the CDTRP. All Innovation Grant applicants are required to outline how their research addresses a patient priority. Applicants must outline the significance, feasibility, and integration of PFD in their project.
The proposed application should describe a ‘stand alone’ project. The grant is not meant to complete funding for larger projects. The study must be completed within 18 months of receipt of funding; no renewals will be considered and extensions beyond 18 months will be considered under exceptional circumstances only.
Non-eligible Research Proposals
The following types of proposals will not be eligible:
- Proposals for projects that have received funding from another source, including government or industry sponsors, will not be eligible to receive a CDTRP Research Innovation Grant unless said funding is shown by the applicant to be directed to a portion of the overall project/research that is separate and distinguishable from the portion to which the proposal relates.
- Proposal budgets more than $30,000 CAD will not be considered unless there are confirmed leveraged funds from another source.
- Proposals for pharmaceutical product development (including studies on non-approved indications for drugs) and/or product comparison, or product promotion will not be considered.
- Successful applicants from the 2023 CDTRP Research Innovation Grant competition will not be considered for this competition. Applicants may submit multiple unique applications to the CDTRP Research Innovation Grant competition; however, only one award can be accepted from the CDTRP Research Innovation Grant competition per year.
- Investigators who have final project reports outstanding from CDTRP at the application deadline will not be eligible to receive a CDTRP funded grants.
- Investigators who have final project reports outstanding from any TRFBC competition at the application deadline will not be eligible to receive the TRFBC funded grants.
- Investigators who have final project reports outstanding from any KFOC competition at the application deadline will not be eligible to receive the KFOC funded grants.
- Grant funds may not be used for clinical training.
For the 2024 competition, the CDTRP is proud to partner with the following organizations to provide funding to support a total of 9 grants of $30,000 CAD each:
- Takeda Canada [1]
- Transplant Research Foundation of British Columbia:
- The Venture Grants [2]
- Kidney Foundation of Canada [2]
- Alberta Transplant Institute / Paladin Labs Inc. [1]
- London Health Sciences Centre [1]
- Université de Montréal [2]
The total value of the competition is $270,000, enough to support 9 grants of $30,000 CAD each (pending availability of partner funding).
Of the $270,000, we will support grants in the following strategic areas:
- 1 grant of $30,000 CAD to support new research that aligns with the CDTRP’s mission and with one of the 5 Themes. This will be provided through the CDTRP Research Innovation Grant competition over an 18-month performance period with funding provided by Takeda Canada.
- 2 grants of $30,000 CAD each to support new and innovative research primarily focused on adult and/or pediatric solid organ transplantation and donation that aligns with the CDTRP’s mission and with one of the 5 Themes. Projects must include a patient, family, donor (PFD) engagement component in their design, detailing how PFD partners will be meaningful engaged in the research as a team member. Projects with a secondary focus on hematopoietic cell transplant must clearly outline how the intended research relates to solid organ donation or transplant research in order to be considered for this award. Please contact newlife@trfbc.org with any questions related to the above requirements. The Principal Applicant must hold the rank of assistant professor or higher and be based in British Columbia. The study can involve additional co-researchers, other sites and patients from across the country, provided the majority of research is conducted in British Columbia. The Transplant Research Foundation of BC/CDTRP Venture Grants will be funded by the Transplant Research Foundation of British Columbia over an 18-month performance period.
- 2 grants of $30,000 CAD each to support new research related to kidney donation and/or transplantation that aligns with the CDTRP’s mission and with one of the 5 Themes. These projects can fall under any of the four research pillars of the KFOC (biomedical, clinical, health systems, & population health). The Kidney Foundation of Canada encourages research projects which include lived-experience expertise on the application team, although this is not mandatory. KFOC will require Foundation specific financial and scientific reporting, for any questions, please reach out to marquis@kidney.ca. Please note that KFOC will only approve one, 6 month no cost grant extension under exceptional circumstances. The CDTRP KFOC Research Innovation Grants will be funded by The Kidney Foundation of Canada over an 18-month performance period.
- The Alberta Transplant Institute (ATI) in partnership with Paladin Labs Inc. will provide 1 additional grant of $30,000 CAD each to the top ranked unfunded Alberta-based researchers through the CDTRP ATI/Paladin Research Innovation Grant competition over an 18-month performance period.
- The London Health Sciences Center will provide 1 additional grant of $30,000 CAD to the top ranked unfunded LHSC researcher through the CDTRP LHSC Research Innovation Grant competition over an 18-month performance period.
- The Université de Montréal will provide 2 additional grants of $30,000 CAD to the top ranked unfunded UdeM researcher through the CDTRP UdeM Research Innovation Grant competition over an 18-month performance period.
Each grant will be awarded to the successful applicant(s) via the Primary Applicant’s institution.
Research Proposal and Figures/Tables:
- The research proposal should be novel, previously unpublished and not exceed 3 pages (not including references), with a maximum of 3 additional pages for figures or tables.
- Suggested headings include 1) Statement of Objective(s), 2) Recent relevant research by applicant, 3) Brief review of literature and background information, 4) Hypothesis(es), 5) Design and Methodology, 6) Analysis of Data, 7) Anticipated Timeline, and 8) Impact, Future research plans and Knowledge Translation.
In addition to the 3-page proposal, the application must include:
- The contact information requested in the application form, including the optional EDI questions. This page will be removed from your application prior to review.
- The names of individuals that should NOT review your application, with justification.
- A half-page summary of the research proposal that highlights how the research proposal helps achieve the CDTRP’s mission, which is to drive advances in Canadian donation and transplantation research and mobilize knowledge so that every wish to donate is fulfilled and transplantation is transformed from a treatment to a lasting and sustainable cure. This summary will be used by the CDTRP and shared with funding partners to assess the relevance of the application to the scope of the competition. (max ½ page)
- A lay abstract (max 250 words) that can be used to explain the proposal to PFD reviewers and the general public and that could be posted publicly if funded. This abstract should be free of jargon, technical or undefined scientific terms, and written in a manner that is easily understood by someone without prior knowledge of the subject. To help you with the lay abstract, you can use these tools: Hemingway & Health Research BC.
- References (no page limit)
- A one page description of the budget and justification. Note that PFD remuneration is an eligible expense and should be included if you have PFD partners on your project.
- A separate description of how the proposal will integrate within a specific Theme of the CDTRP (max ½ page).
- An explanation of how sex, as a biological variable, gender, as a socio-cultural factor, and diversity are taken into account in the research design, methods, analysis and interpretation, and/or dissemination of findings, or explain why they are not relevant / feasible within the scope of the project. For guidance and resources on how to integrate sex and gender into research, please consult the CIHR website. (max ½ page).
- Engaging patients, families, and donors in CDTRP support research is a core value for our Network. As outlined in CDTRP’s PFD Terms of Reference, patient engagement requires meaningful and active collaboration between researchers and PFDs in governance, priority setting, conducting research, and knowledge translation.
Engaging PFD partners, especially at the beginning of the project, will help direct research that focuses on patient priorities and improves patient outcomes. Note, CDTRP recognizes that the level of engagement will be different depending on the scope of your project and scientific design.
All Innovation Grant applicants are required to outline how their research addresses a patient priority and outline the significance, feasibility, and integration of PFD in their project.
All applications must answer the below questions (max 1 page).
- Describe how this project supports patient, family, or donor priorities.
- Describe how your research question and design consider the potential impact of PFD involvement.
- Describe how you’ve actively engaged with PFD partners, thus far. If you have not engaged yet, describe the key roles and responsibilities you envision for PFD partners. If not applicable, state why.
- Describe how your project has been strengthened with PFD involvement. If you have not engaged yet, describe how your project will benefit from PFD engagement. If not applicable, state why.
CDTRP’s PFD Partnership Platform Manager Manuel Escoto (mescoto@cdtrp.ca) would be pleased to provide support and feedback as you are developing your application.
In addition, you may reference the resources below when developing your plan.
- CIHR Patient Engagement Training
- Saskatchewan Centre for Patient-Oriented Research
- Alberta SPOR Support Unit
- Michael Smith Health Research BC Resource Library
- Newfoundland and Labrador Support Unit
- BC Patient Safety & Quality Council, A Guide to Patient Engagement
- Can-SOLVE CKD Network Training Modules
- Evidence-Informed Practices and Strategies for Patient-Oriented Research (POR): A ‘Menu’ for Research Teams
Note: PFD remuneration ($50/hr) is an eligible grant expense. For more information on the CDTRP PFD platform, please visit our website: CDTRP PFD Partnership platform. All applications for TRFBC grants must include a PFD Engagement Plan that clearly outlines how PFD partner(s) are meaningful engaged in the research process as a team member.
- A copy of a CIHR BioSketch Common CV for the Principal Applicant.
- Optional: Applicants may also include letters of support and/or commitment from the Chair of the Department/Division indicating the level of institutional and/or university support.
The completed application must be submitted electronically (by using the link) no later than 11:59pm PST on March 26, 2024. The magnitude of the project should match the size of the award; the award is not intended to supplement a major grant; however, it is anticipated that this funding will be used to produce data to apply for large/national level grant funding.
Failing to comply with these requirements may negatively impact the evaluation of your application; it could lead to CDTRP withdrawing your application or reformatting it and removing any pages that exceed a page limit, without notifying you. Documentation received after the submission deadline will not be submitted for review. The applicant is responsible for ensuring completeness of the application and incomplete or unsigned applications will not be considered. Applicants must submit their application electronically using this link.
The applicant must use Calibri or Arial font, size 12 points or larger. Use at least 2 cm (3/4 inch) margins (top, bottom, left, and right) for all pages. The section name and the name of the Principal Applicant should appear in the header.
Qui peut postuler au concours de subventions à l’innovation ?
Le candidat principal doit être autorisé à détenir des fonds dans une institution canadienne. Pour accepter la bourse, le demandeur principal doit devenir membre.
Le PRDTC m’écrira-t-il une lettre de soutien pour ma demande ?
Une lettre du PRDTC est inutile : pour ce concours, nous avons le rôle d’agence de financement.
Les fonds provenant de ces subventions peuvent-ils être utilisés pour l’achat d’équipements ?
Le concours de subventions à l’innovation est une subvention de « recherche » et non une subvention d’« équipement », et la demande doit donc vraiment être axée sur les activités et les résultats de la recherche. Toutefois, si vous avez besoin d’un nouvel équipement pour effectuer la recherche, il s’agit d’une dépense admissible.
Y a-t-il une limite au nombre de co-candidats ?
Le nombre de co-candidats n’est pas limité.
Comment puis-je intégrer mon projet dans le PRDTC ?
Voici quelques façons d’intégrer un projet dans le réseau du CDTRP :
- Inscrivez tous les stagiaires travaillant sur le projet sur la Plateforme d’éducation et formation du PRDTC ;
- Contactez Manuel Escoto (mescoto@cdtrp.ca) pour vous assurer que le plan de participation des patients est solide et pour obtenir de l’aide afin d’identifier les partenaires patients ;
- Publiez les résultats du projet en langage clair sur le Portail des patients du CDTRP ;
- Présentez votre projet lors d’une réunion d’un des thèmes du PRDTC – particulièrement utile si vous cherchez à collaborer avec d’autres membres du thème.
Comment puis-je préparer mon plan d’engagement des patients ?
L’engagement des patients, familles et donneurs (PFD) partenaires est une valeur fondamentale du PRDTC. Alors que vous préparez votre demande Concours de subventions à la recherche et à l’innovation du PRDTC, utilisez ces ressources pour élaborer votre plan d’engagement des PFD.
ity of Alberta and has received training in patient-oriented research through the University of Calgary’s PACER (Patient and Community Engagement Research) Program. He is the Patient, Family, and Donor Partnerships & Education Manager with the Canadian Donation and Transplantation Research Program. In this role, Manuel builds relationships patient partners with investigators and strengthens capacity among CDTRP patient partners.
Anders Billström 
Gareth Wiltshire
K
Sherrie Logan 
born and raised in Edmonton, AB. With a degree in Music Performance (saxophone performance) and Education, Lindsey has taught for over a decade in the Edmonton Public School system. When she is not teaching, she is very involved in the music community, performing in the Edmonton Winds, conducting her own community ensemble (The Beer League Band) and on numerous musical boards across the province. For the past 5 years, Lindsey has had to take a break from teaching after having her amazing son, George. Maternity leave did not goes as expected as George was diagnosed with Dilated Cardiomyopathy at 5 months old and required 2 heart transplants before the age of 4. During this time, Lindsey has also began to dedicate her time building and expanding her charity: Big Gifts for Little Lives, where they raise money to fund Pediatric Heart Transplant research at the Stollery.
Dr. Caigan Du is a scientist at the Vancouver Coastal Health Research Institute and an assistant professor in the Department of Urologic Sciences at the University of British Columbia. He received a Ph.D. degree in Biochemistry in UK and postdoctoral training in Immunology in USA. He is interested in the pathogenesis of kidney ischemia-reperfusion injury and transplant rejection, and molecular control of urinary malignancies. He has been studying the impact of kidney donor-derived factors on renal allograft rejection, and the molecular pathways of kidney injury and regeneration in experimental models. He is also interested in developing medical solution including drugs made from natural compounds for all kinds of health problems, including immune disorders, organ preservation, kidney failure and urinary cancer. He is the PI of many grant supports from the Kidney Foundation of Canada and the Canadian Institutes of Health Research.
Heather Badenoch is a non-directed living liver donor and communications strategist. As the president of Village PR, she provides strategic communications direction and training to not-for-profit clients in community and health. An active transplant volunteer, Heather helps transplant candidates find living donors by running their public appeals, small and large, pro-bono. She also mentors potential living donors on the path to living donation. Heather is a volunteer with the UHN Centre for Living Organ Donation and the Canadian Donation and Transplant Research Program. She and her spouse adopt rescue dogs and volunteer together with Community Veterinary Outreach, a group providing free veterinary care to the pets of people who are homeless.
Sean Dicks is a clinical psychologist who has 20 years’ experience supporting both families of organ donors and transplant recipients. While it is rare for him to have contact with a donor family and recipient linked to the same organ donation-transplantation event, his contact with families who have lived experience with organ donation on the one hand, and patients who have received transplants on the other hand has provided opportunities to explore how their journeys become linked when they attempt to make sense of and find meaning in their respective crises.
Terri Hansen-Gardiner is a Cree speaking Metis woman from Northern Saskatchewan as well as a 10 year Breast Cancer Survivor. Her tireless spirit and dedication to her community is undeniable. Terri is a cancer survivor who travels around the province to provide assistance, information, and support to Indigenous patients who are trying to access and navigate the cancer care system.
Dr. Golnaz Karoubi is Assistant Scientist at the Toronto General HospitalResearch Institute and principal investigator in the Latner Thoracic Research Labs. She currently holds an Assistant Professor appointment in the department of Laboratory Medicine and Pathobiology and a cross-appointment in the department of Mechanical and Industrial Engineering at the University of Toronto. Dr. Karoubi received her PhD in Applied Science and Engineering at the University of Toronto and joined the Lung Regenerative Medicine Program in the Department of Clinical Research in Berne University, Switzerland for a post-doctoral research fellowship. She stayed on as a Group Leader in 2008 to direct the basic and transitional science as related to Cancer Stem Cell and Lung Regenerative Medicine in the Department of Biomedical Research at the University of Berne until 2012. In early 2012, she joined the team of Dr. Tom Waddell at the Toronto General Hospital Research Institute as a Senior Scientific Associate and was appointed to Assistant Scientist at the Toronto General Hospital Research Institute (University Health Network) in November 2019 and to Assistant Professor in the Department of Laboratory Medicine and Pathobiology in July 2020.
Dr. Haykal graduated from the University of Ottawa Faculty of Medicine in2007 as class valedictorian and silver medalist, and subsequently completed her residency training in Plastic and Reconstructive Surgery at the University of Toronto in 2016. During her residency, she completed a four-year Doctorate of Philosophy (PhD) in tissue engineering, regenerative medicine and immunology with a focus on tracheal reconstruction. She obtained numerous grants and awards including a CIHR Vanier Scholarship. Dr. Haykal then pursued fellowship training in microsurgical reconstruction at the Albany Medical Centre in New York. Dr. Haykal joined the University Health Network and the Toronto General Hospital in 2018. Her clinical focus is on complex oncological reconstruction and microsurgical reconstruction of the breast, head and neck and extremity. She started a lymphedema program in 2019 where she offers microsurgical techniques for the treatment of lymphedema.
Dr. Ahmed is a Professor in the Cumming School of Medicine at the University of Calgary. The recipient of the 2022 Hypertension Canada Senior Investigator Award, she is a nephrologist and clinician-scientist with a focus on sex and gender differences in human cardiovascular/kidney physiology and clinical outcomes. Dr. Ahmed is the Vice Chair (Research) for the Department of Medicine, Lead of the Libin Institute Women’s Cardiovascular Health Research Initiative at the University of Calgary and Lead of the Alberta Strategy for Patient Oriented Research Capacity Development Platform. Dr. Ahmed is an Advisory Board member for the Canadian Institutes of Health Research Institute of Gender and Health, a member of the Canadian Medical Association Journal Governing Council and the President-Elect for the Organization for the Study of Sex Differences.
r. Christopher Nguan is an Associate Professor at the University of British Columbia in the Department of Urological Sciences, Surgical Head of Kidney Transplantation at Vancouver General Hospital and the Director of the Surgical Technologies Experimental Laboratory & Advanced Robotics (STELLAR) facility at Vancouver General Hospital.
r Caroline Lamarche is a clinician scientist and transplant nephrologist at Maisonneuve-Rosemont Hospital. She is an assistant clinical professor at the Université de Montréal. After her nephrology training at the Université de Montréal (2015), she completed a Master degree on the use of adoptive immunotherapy to treat/prevent BK nephropathy in kidney transplant recipients. She then pursued a post-doctoral fellowship with Dr. Megan Levings at the University of British Columbia on the use of chimeric antigen receptor (CAR) regulatory T cells (Tregs) to induce transplant tolerance. Her lab is working on the development of adoptive immunotherapy in nephrology and understanding Treg dysfunction.
Dr. Tandon is an Associate Professor of Medicine, Co-Director of the Cirrhosis Care Clinic, Transplant Hepatologist and lead of the Cirrhosis Care Alberta quality improvement program. She obtained her training at the University of Alberta, the Hospital Clinic in Barcelona and Yale University. Her clinical practice and research are focused on cirrhosis with research interests including cirrhosis related complications, malnutrition, frailty, exercise therapy, palliative care, integrative health approaches such as meditation and knowledge translation. It is her career goal to provide wholistic, interdisciplinary, evidence based, patient-centered care through education, empowerment, engagement and team-work.
Emily is a PhD student at the University of Alberta, where she completed her Master of Science (MSc) degree in medicine. With a passion for patient-oriented research and a commitment to improving health outcomes, Emily’s doctoral project focuses on EMPOWER, a 12-week online mind-body wellness program designed for adults living with chronic health conditions.
Dr Basil S. Nasir, M.B.B.Ch
Dr. Victor Ferreira is an Assistant Scientist in the Ajmera Transplant Centre at the University Health Network (UHN) and the Toronto General Hospital Research Institute (TGHRI). He is also an Assistant Professor at the University of Toronto in the Department of Laboratory Medicine and Pathobiology (LMP). He completed his PhD in Medical Sciences – Infection and Immunity Specialization at McMaster University in 2014 and post-doctoral training at UHN. His research program is focused on three pillars: I) using systems vaccinology to reveal insights into vaccine responses in immunocompromised individuals like transplant recipients; II) characterizing the impact of chronic viral infection on host immune responses; and III) developing novel methods for eliminating latent viruses in human organs. His work has been cited >2,500 times and is published in journals including the New England Journal of Medicine, Nature Immunology, the Lancet Infectious Diseases, Clinical Infectious Diseases, the American Journal of Transplantation and Journal of Infectious Diseases.
Chemical Engineering as an Assistant Professor in August 2014. She is a biochemical engineer with expertise in bioprocess development, high‑throughput screening and stem cell culture optimization. Her research aims to develop bioprocesses to produce and transplant therapeutic cells to treat diabetes and cardiovascular disease. She notably developed new methods to encapsulate pancreatic islets, as well as vascular biomaterials surface modification strategies which are now applied by other researchers around the world. Her emerging leadership in bioengineering was recognized through the 2014 Martin Sinacore Outstanding Young Investigator Award from Engineering Conferences International & Biogen Idec, as well as the “Étoiles effervescence” award from Montreal InVivo.
Chantal Bémeur is a nutrition specialist in relation to liver disease and its many complications. Professor Bémeur trained as a dietitian/nutritionist and completed her graduate studies and two post-doctoral fellowships in nutrition, focusing on conditions affecting the hepatic and nervous systems, such as hepatic encephalopathy and Leigh Syndrome French Canadian. Professor Bémeur’s research activities are generally of a fundamental and clinical nature, including a collaboration with CHUM’s Department of Hepatology and Gastroenterology. As an expert member of the International Society on Hepatic Encephalopathy and Nitrogen Metabolism, Dr. Bémeur has participated in the development of guidelines on nutrition and liver disease. She is also part of a team of Canadian experts who developed an evidence-based nutritional education guide collaborating with people with chronic liver disease and their caregivers. She received an award from the Ordre professionnel des diététistes du Québec in 2018 for her work on this guide. Dr. Bémeur has published several book chapters, 30 scientific articles and over 100 scientific abstracts. Dr. Bémeur’s co-directs the HepatoNeuro Laboratory in the Cardiometabolic Axis of the Centre de recherche du Centre hospitalier de l’Université de Montréal (CRCHUM). Several organizations, including the Donation and Transplantation Research Program of Canada and the Canadian Institutes of Health Research fund Dr. Bémeur’s research.
Dr Thozama Siyotula is a distinguished paediatric surgeon at Red Cross War Memorial Children’s Hospital in Cape Town, South Africa. With a profound interest in hepatobiliary, transplant, thoracic and neonatal surgical outcomes. She completed her undergraduate training in 2011 at the University of the Witwatersrand in Johannesburg. Furthering her studies she went on to specialise in paediatric surgery through the Colleges of Medicine of South Africa, completing her FCPaedSurg (SA) in 2021 and a master’s in medicine (Paediatric Surgery) in 2021 at the University of Cape Town. She currently works as a paediatric surgeon and transplant surgeon. A senior lecture at the University of Cape Town and course convenor for the 5th year undergraduate paediatric surgery program at the University of Cape Town.
David Thomson is a critical care subspecialist and abdominal transplant surgeon at Groote Schuur Hospital and the University of Cape Town. His interests are deceased donation, ECMO, medical education and system improvement. He created the massive open online course Organ Donation: From Death to Life hosted on Coursera.org to improve education around organ donation and transplantation. He is the immediate past President of the Southern African Transplantation Society and led development on a report on Organ and Tissue Donation in South Africa: Creating a National Strategic Roadmap in collaboration with the International Society for Organ Donation and Procurement. He worked on the World Brain Death Project and is the lead author on the South African Guidelines for Determination of Death published in 2021.
About Dr. Julie Ho
Dr. Tom Blydt-Hansen completed his MD at McGill University, and his Pediatric and Nephrology specialization at the Montreal Children’s Hospital, followed by further specialization in transplantation at the University of California, Los Angeles. He began his Nephrology career at the University of Manitoba in 2001, where he was Division Head of Nephrology from 2005-2014.
Monica Bronowski completed an undergraduate degree in neuroscience at Dalhousie University, with a focus on innovative neurotechnology. Before starting her PhD, she worked in hematology, oncology, and bone marrow transplant (BMT), conducting clinical trials across various study phases for multiple myeloma, bone marrow transplant, and CAR-T therapies. This experience exposed her to both early and late-phase clinical trials, deepening her interest in translational research.
Angela Hamie has just graduated from the University of Alberta and holds a Bachelor of Science with Honors in Immunology and Infection. Her presentation will summarize her research conducted throughout her fourth year undergraduate thesis project, which focuses on the Age, Thymus Excision, Organ Type, and Immunosuppression on Lymphocyte Subpopulations in pediatric transplantation.
Mitchell Wagner is currently a first year medical student at the University of Alberta. He graduated from the U of A in 2022 with an Honors degree in Immunology and Infection with a certificate in biomedical research. He recently defended a Master of Science in Experimental Surgery, focusing on the optimization of out-of-body heart perfusion. Mitchell’s main research interest is on strategies that improve donated organs through ex-situ heart perfusion apparati, however has also been involved in clinical research within the areas of radiology, respiratory medicine, and cardiology. Mitchell is the recipient of multiple prestigious awards such as the Canada Graduate Scholarship – Masters and the Cote Biomedical Research Studentship. As an aspiring surgeon-scientist, he intends on completing an MD/PhD program focusing to further improve out of body heart perfusion protocols.
Sarjana Alam is an undergraduate science student at the University of Alberta, where she is a research trainee under the supervision of Dr. Esme Dijke in the Department of Laboratory Medicine & Pathology. She is involved in a project investigating the cryopreservation of T regulatory cells for tolerogenic cell therapy.
Marie-Pier joined Dre. Marie-Josée Hébert’s lab in the nephrology, transplantation and renal regeneration research unit at the CRCHUM in 2024. She obtained her BSc degree in biology at McGill university and is now pursuing a Masters degree in the Molecular Biology program at l’Université de Montréal. She is currently working on evaluating the pro-angiogenic potential of RNAs enriched in apoptotic exosomes and whether these RNAs cooperate to modulate endothelial function. Marie-Pier is also a trainee in the Canadian Donation and Transplantation Research program (CDTRP).Outside of the lab, Marie-Pier loves to read, go to spin classes and play word games like Scattegories and Bananagrams.